← Back to headlines
Royalty Pharma plc Exceeds Expectations with Strong 2026 Growth Outlook
Royalty Pharma plc (RPRX) has been given a $51 target as its growth outlook for 2026 surpasses market expectations, indicating strong future performance.
4 Mar, 00:22 — 4 Mar, 00:22
Sources
Showing 1 of 1 sources
